A nucleotide sequence is provided which encodes a peptide having beta-xylosidase activity and exhibits at least 30% amino acid identity with the amino acid sequence shown in SEQ ID NO. 1 and described in SEQ ID NO. 3 or hybridises under stringent conditions with a nucleotide sequence shown in SEQ ID NO. 1, or a part thereof having at least 15 nucleotides encoding an amino acid sequence shown in SEQ ID NO. 1 and described in SEQ ID NO. 3. Also provided is a peptide having beta-xylosidase activity and exhibiting at least 30% amino acid identity with the amino acid sequence shown in SEQ ID NO. 1 and described in SEQ ID NO. 3 or a part thereof having at least 8 amino acids shown in SEQ ID NO. 1 and described in SEQ ID NO. 3.
1. Recombinant cell derived from a host cell having a β-xylosidase gene, wherein said recombinant cell comprises a β-xylosidase gene that has been disrupted by a mutation in a nucleotide sequence of said β-xylosidase gene, said β-xylosidase gene prior to disruption encoding a peptide having β-xylosidase activity, said peptide comprising at least 60% amino acid identity in the primary sequence with the amino acid sequence of SEQ ID NO: 3. 2. Recombinant cell derived from a host cell having a β-xylosidase gene, wherein said recombinant cell comprises a β-xylosidase gene that has been disrupted by a mutation in a nucleotide sequence of said β-xylosidase gene, said nucleotide sequence hybridizing under stringent conditions with a nucleotide sequence of SEQ ID NO: 1. 3. A method for the production of a xylanolytic enzyme preparation, which is essentially free of β-xylosidase activity, comprising culturing said recombinant cell according to claim 1 and obtaining enzymes from the culture medium. 4. Method according to claim 3 wherein the preparation is an endoxylanase-containing preparation.
The present invention relates to a novel peptide having β-xylosidase activity, to a nucleotide sequence encoding such a peptide, and to the use of such a β-xylosidase-like peptide. Beta-xylosidase (1,4-β-D-xylan-xylohydrolase; EC 3.2.1.37) is one of the xylanolytic enzymes. Xylans are a major constituent of the cell walls of plants, and are second only to cellulose. They are abundantly found in most land plants, especially in agricultural by-products such as straw, wheat-bran, corn cobs, cotton seed, etc. Xylan is a complex polymer consisting of a β-1,4-linked xylose polymer with arabino-furanose, glucuronic acid, methylglucuronic acid and acetyl side-groups. Endoxylanase (EC 3.2.1.8) randomly cleaves the β-1,4-bonds in the xylan backbone to yield oligosaccharides, xylobiose and xylose. Beta-xylosidase cleaves terminal xylose units from the non-reducing end of the xylose oligomers resulting from endoxylanase activity. α-Glucuronidase cleaves glucuronic acid side groups from backbone xylose units, whereas α-L-arabinofuranosidases (EC 3.2.1.55) cleave arabinose units from the xylan backbone and acetylesterases (EC 3.1.1.6) remove the acetyl side-groups. Beta-xylosidase is also effective in transglycosylation reactions wherein monosaccharide units or alcohols are attached to or cleaved from xylose units. Beta-xylosidase is rate-limiting in xylan hydrolysis (Dekker 1983, Poutanen and Puls 1988). The hydrolysing and transglycosylating reactions of β-xylosidases are economically important for the breakdown and utilisation of agricultural waste material e.g. in the production of xylose, xylose oligomers and xylitol, which are useful as sweeteners in foodstuffs, candies and medicaments, especially as a sugar substitute. Also, the enzyme or its products can be used as bread improvers and in the beer brewing industry. Beta-xylosidases have been isolated from various sources including bacteria and fungi. For example, the purification of β-xylosidase from Three endoxylanases and one β-xylosidase were isolated from Beta-D-xylosidase from rumen fungus Known β-xylosidases have activity patterns that do not always correspond to the industrial needs. In particular it is often desirable that the enzyme has a high xylosidase specificity and low specificities for other substrates, such as glucosides and galactosides. Especially fungal β-xylosidases are highly advantageous for their activity levels and specificity patterns. In order to be able to provide β-xylosidase-like enzymes having the desired activity patterns from the desired production organisms, sequence information of the β-xylosidase gene should be available. Up to now however, no sequence information on fungal β-xylosidases has been reported. A novel β-xylosidase has now been found and its amino acid sequence as well as its encoding nucleotide sequence have been determined. The protein is denoted herein as xylD, whereas the encoding gene is denoted as xlnD. The primary structure of the novel β-xylosidase appears to be different form known β-xylosidase-like enzymes. Also, its activity pattern is different form known β-xylosidase-like enzymes, and its xylosidase activity is about two times higher than that of the β-xylosidase reported by Rodionova et al (supra). Accordingly, the invention relates to a nucleotide sequence encoding a peptide having β-xylosidase activity and exhibiting at least 30% amino acid homology with the amino acid sequence shown in SEQ ID NO. 1 and described in SEQ ID NO. 3 or hybridising under stringent conditions with a nucleotide sequence shown in SEQ ID NO. 1, or a part thereof having at least 15, preferably at least 21, more preferably at least 24 or even at least 30 nucleotides encoding an amino acid sequence shown in SEQ ID NO. 1. By amino acid homology is meant here amino acid identity in the primary structure. Amino acid similarity is usually higher than the figures given for identity. In this context, heterologous hybridisation conditions are as follows: hybridisation in 6×SSC (20×SSC per 1000 ml: 175.3 g NaCl, 107.1 g sodium citrate.-5H2O, pH 7.0), 0.1% SDS, 0.05% sodium pyrophosphate, 5* Denhardt's solution (100×Denhardt's solution per 500 ml: 10 g Ficoll-400, 10 g polyvinylpyrrolidone, 10 g Bovine Serum Albumin (Pentax Fraction V)) and 20 μg/ml denatured herring sperm DNA at 56° C. for 18-24 hrs followed by two 30 min. washes in 5×SSC, 0.1 % SDS at 56° C. and two 30 min. washes in 2×SSC, 0.1% SDS at 56° C. The nucleotide sequence of the invention encodes a peptide having substantial β-xylosidase activity, i.e. it has β-xylosidase activity as its predominant enzymic activity, and thus may be used for the production of β-xylosidases or mutants thereof. The coding sequences may contain mutations (insertions, deletions or both) which serve to modify the structure and/or the activity of the expression product. For an active expression product, the minimum identity and/or the hybridisation characteristic as defined above should preferably be maintained. The nucleotide sequence may also correspond to regulating or signal sequences of β-xylosidases. For these uses, the nucleotide sequence comprises substantially the encoding or regulating sequences of the β-xylosidase. On the other hand, the nucleotide sequence may be used as a primer or probe in detecting β-xylosidase encoding sequences. For these uses, the sequence comprises at least 15, up to e.g. 60, consecutive nucleotides of the sequence of SEQ ID NO. 1. The invention also relates to an isolated peptide having β-xylosidase activity and exhibiting at least 30% amino acid homology (identity) with the amino acid sequence shown in SEQ ID NO. 1 and described in SEQ ID NO. 3 or a part thereof, said peptide having no β-glucosidase and/or no β-galactosidase activity; essentially no β-glucosidase or β-galactosidase activity means that these activities are less than 2%, in particular less than 1% of the β-xylosidase activity. A peptide exhibiting at least 40%, preferably at least 60%, most preferably at least 75% amino acid identity with the amino acid sequence shown in SEQ ID NO. 1 and described in SEQ ID NO. 3 forms a preferred embodiment of the invention. Also part of the invention are peptides comprising a series of at least 8 contiguous amino acids of the amino acid sequence shown in SEQ ID NO.1. These can be produced by translating a nucleotide sequence as described above. Preferably the peptide has a contiguous series of at least 10, most preferably at least 12 amino acids from the sequence set forth in SEQ ID NO. 1and described in SEQ ID NO. 3. The peptide according to the invention is especially from fungal origin, in particular from filamentous fungi, e.g. strains from the genera Aspergillus (especially Also, the invention concerns antibodies raised against a peptide as described above e.g. for purifying β-xylosidases and for determining the presence of β-xylosidases. The antibodies can be produced by immunisation with the peptide described above, using hybridoma techniques which are well-known to the skilled person. Also claimed are expression vectors and plasmids containing the nucleotide sequences described above under the control of a homologous or heterologous promoter. Furthermore, the invention is concerned with the use of these sequences for the production of β-xylosidases by different hosts under the control of its own, or heterologous regulatory sequences, or for the production of other peptides using the β-xylosidase promoter sequence. The expression vectors and host cells may contain multiple copies of the xylD-encoding sequences (altered or not with respect to SEQ ID NO. 1) and of other genes. Host organisms may be homologous production strains or alternatively heterologous hosts. Suitable host organisms include fungi, yeasts, bacteria and plants. Examples are Aspergillus species, Trichoderma species, Bacillus species, Kluyveromyces species, Saccharomy,ces species and Fusariuni species. Particularly preferred are Examples of own control regions and heterologous regulatory regions include fungal constitutive and/or inducible promoters such as the pyruvate kinase promoter (pkiA) and the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoters. Examples of strong yeast promoters are alcohol dehydrogenase, 3-phosphoglycerate kinase and triose phosphate isomerase promoters. Examples of bacterial promoters are α-amylase, spo2 and promoters of extracellular protease genes. The invention is furthermore concerned with the use of regulatory sequences contained in the 5′-noncoding part of SEQ ID NO.1 (nucleotides 1-854 or a part thereof) for expression of homologous or heterologous genes, e.g. xylanase, amylase, glucanase, oxidoreductases e.g. hexose oxidase, α-glucuronidase, lipase, esterase, ferulic acid esterase, proteases, or human interleukin-6, bovine (pro)chymosin, human lactoferrin, fungal phytase. A signal sequence of xlnD may be used in such constructs, as well as a suitable terminator, e.g. xlnD or trpC. Further part of the invention is the use of the nucleotide sequence described above in such a manner as to disrupt the β-xylosidase gene of a host organism. To this end a nucleotide sequence containing a mutation which brings about a defunctionalisation of the β-xylosidase gene is introduced in the host cell. The mutation may be a deletion of one or more nucleotides, an insertion of one or more nucleotides, or a combination thereof. The host cell—whether altered so as to produce or overproduce β-xylosidase or so as not to produce its β-xylosidase—may advantageously express or overexpress other relevant proteins, including enzymes, in particular other xylanolytic enzymes such as endoxylanases, and/or other enzymes such as amylases, glucanases, oxidoreductases such as hexose oxidase, α-glucuronidase, lipases, esterases, ferulic acid esterase and/or proteases. The corresponding genes may be under the control of homologous control regions or under the control region of the β-xylosidase gene contained in the nucleotide sequence described above. An especially suitable protein to be expressed by the recombinant host cell according to the invention is the activating regulator of the xylanolytic pathway denoted as xylR. The target genes for this regulator comprise the genes xlnA, xlnB, xlnC (all three endoxylanase-encoding genes), xlnD and axeA. Thus, the host cells according to the invention containing the xlnR gene, i.e. capable of expressing xylR or an active equivalent thereof, are effective producers of β-xylosidase—in case they contain the active xlnD gene—or of other xylanolyitc enzymes including endoxylanases, excluding β-xylosidase—in case their xlnD gene has been defunctionalised. The nucleotide sequence of the xlnR gene is set forth in SEQ ID NO.2. Also comprised by the invention is the use of the enzyme activity of the peptide in transglycosylation reactions of substrates contained in bread doughs and other bakery products, resulting in improved bread characteristics. This includes the use of the β-xylosidase as a bread improver in a manner known per se for enzymic bread improvers. The β-xylosidases encoded by the present sequences can also be advantageously used for the production of xylose and xylose oligomers from wood and plant wastes and spent paper pulp, which xylose and oligomers are suitable as sweeteners. They can also be reduced to xylitol, which is also an effective bulk sweetener. The host cells according to the invention, wherein the β-xylosidase gene has been disrupted, can be used e.g. in the production of enzymes and enzyme preparations e.g. to be added to animal feed. Animals, including poultry and pigs, have a poor metabolism for xylose (Schulte, 1991). Xylose which is absorbed over the gut wall occupies the urinary excretion system land thus xylose uptake is energetically dis-advantageous to the animal. Moreover, a high intake of xylose is known to cause cataracts, diarrhoea and anorexia. On the other hand xylose and xylo-oligomers can be fermented to short chain fatty acids, which is an energetic asset. Therefore hemicellulose-degrading enzymes in feed should produce xylo-oligomers and no xylose monomers, and thus the enzymes should have endoxylanase activity and no, or a reduced level of, β-xylosidase activity. Thus the inventions also pertains to the use of host cells, such as fungi, bacteria, yeasts and plants, having a defunctionalised β-xylosidase gene but being capable of effectively producing endoxylanase and optionally other, especially xylanolytic, enzymes, for the production of enzyme preparations free of β-xylosidase. The invention also comprises such xylanolytic enzyme preparations lacking β-xylosidase activity. The β-xylosidase encoded by the nucleotide sequence of SEQ ID NO. 1 differs greatly from the β-xylosidase of Table A summarises the specificity pattern of two β-xylosidases X-I and X-II of the invention—presumably differing only in their glycosylation pattern, not in their amino acid sequence—and of the β-xylosidase reported by Rodionova et al., and their inhibition by xylose. The amino acid composition of these β-xylosidases is given in table B. Mutant strain DEAE-Sephadex A-50 was equilibrated in 50 mM sodium acetate buffer pH 5.0 and was added to the culture filtrate. After 30-60 minutes of stirring at 4° C., the DEAE-Sephadex together with the culture filtrate were passed through a funnel with a glass filter holder and the DEAE-Sephadex A-50 was transferred to a column. This column was first eluted with 50 mM sodium acetate buffer pH 5.0, then with 50 mM sodium acetate buffer pH 5.0+0.5 M NaCl. Fractions containing β-xylosidase activity, as was detected using the chromogenic substrate 4-methylumbelliferyl-β-D-xyloside (detects β-xylosidases and endo-xylanases) (Sigma #M7008), were pooled and desalted by dialysis against Millipore water and subsequently dialysed against 20 mM piperazine-HCl buffer pH 5.0. After dialysis the sample was loaded on a DEAE-Sepharose Fast Flow column. This column was first eluted with 3 volumes 20 mM piperazine-HCl buffer pH 5.0 and then with a linear gradient of 0.5 M NaCl in 20 mM piperazine-HCl buffer pH 5.0. Detection of the eluted protein was performed by continuous measurement of the UV absorption at 280 nm (FIG. 1). Fractions of 10 ml were collected which were assayed for activity of β-xylosidase on para-nitro-phenyl-β-D-xylopyranoside (PNP-X) (Sigma #N2132). The β-xylosidase was found in fractions 11-27, which were pooled and subsequently dialysed against 20 mM piperazine-HCl buffer pH 6.0 (FIG. 2). 5 ml of the dialysed sample was applied on a Mono Q HR 5/5 column (Pharmacia). Protein was eluted using 59 ml of a linear gradient of 1 M NaCl in 20 mM piperazine-HCl buffer pH 6.0. Detection of the eluted protein was performed by continuous measurement of the UV absorption at 280 nm (FIG. 3). Two peaks containing β-xylosidase activity were found; β-xylosidase I was eluting at 0.19 M NaCl, while peak II eluted at 0.29 M NaCl. SDS-PAGE of both peak fractions revealed that the fractions corresponding with both peaks each contained a single protein band, both having the same apparent molecular weight of 110 kDa. The specific activity of both β-xylosidase I and II towards the artificial substrate PNP-X was determined as described by Rodionova et al., 1983, to be respectively 60.2 and 60.9 U/mg protein. In addition the activity against PNP-β-D-glucopyranoside (Sigma #N7006) was determined to be 0.2 and 0.3 U/mg, against PNP-β-D-galactopyranoside (Sigma #N1252) 0.0 and 0.0 U/mg and against PNP-β-L-arabinofuranoside (Sigma #N3641) 2.8 and 3.4 U/mg respectively for β-xylosidase I and II. cDNA was synthesised from 7 μg poly A+ mRNA and ligated into bacteriophage lambda Uni-ZAP XR using the ZAP™-cDNA synthesis kit (Stratagene) according to the manufacturer's instructions. After ligation of the cDNA into Uni-ZAP XR vector-arms, the phage DNA was packaged using Packagene™ extract (Promega) according to the manufacturer's instructions. Ligation of 120 ng cDNA in 1.2 μg vector arms and subsequent packaging of the reaction mixture resulted in a primary library consisting of 3.5*104recombinant phages. This primary library was amplified using 250 μg of both β-xylosidase I and II was dialysed against 1 mM phosphate buffer pH 7.0 and freeze-dried. The protein was resuspended in 100 μl sterile PBS (0.136 M NaCl; 2.7 mM KCl; 8 mM Na2HPO4; 1.75 mM KH2PO4; pH 7.4). To this protein mixture, 100 μl of Freunds' complete adjuvant was added and vortexed for 30 minutes to obtain a stable emulsion. For both proteins this mixture was injected into a mouse subcutaneously. In week 4 a booster was given by injecting 25 μg β-xylosidase in 100 μl sterile PBS to which 100 μl of Freunds' incomplete adjuvant was added. The mice were bled in week 7 and the serum tested. In week 13 the mice was given a second booster of 25 μg followed by a bleeding in week 14. This procedure of boosters with nn interval of 6 weeks followed by a bleeding may be repeated several times. The collected blood was incubated for 30 minutes at 37° C. and subsequently stored at 4° C. for 16 hours. After centrifugation at 5000 rpm in a Sorvall High speed centrifuge the serum was collected and stored at −20° C. To screen the The cDNA clones expressing β-xylosidase were converted to Bluescript phagemids using super infection with the filamentous helper phage ExAssist™, which is included in the ZAP™-cDNA synthesis kit from Stratagene, according to the manufacturer's instructions. The phagemid DNA was subsequently isolated as described in Sambrook et al. (1989). The isolated DNA of the 4 cDNA clones was subjected to restriction analysis using the restriction enzymes EcoRI and XhoI. The DNA was digested for 2 hours at 37° C. in a reaction mixture composed of the following solutions; 2 μl (≈1 μg) DNA solution; 2 μl of the appropriate 10*React buffer (Life Technologies); 10 U of each restriction enzyme (Life Technologies) and sterile distilled water to give a final volume of 20 μl. After addition of 4 μl DNA loading buffer the samples were loaded on a 0.7% TAE-agarose gel. The DNA fragments were separated by electrophoresis at 80 V for 1.5 hours. The restriction analysis revealed that the cDNA clones had inserts of different sizes of respectively 1.4, 1.5, 2.4 and 2.5 kb. The nucleotide sequences of a part of each of these cDNA's were determined by the dideoxynucleotide chain-termination procedure (Sanger et al., 1977) using the Pharmacia T7 DNA polymerase sequencing kit. The sequences obtained revealed that these cDNA's correspond all four to the same gene. For the screening of the This screening resulted in about 50 positive phages, of which ten were purified. Each positive plaque was picked from the plate using a Pasteur pipette and the phages were eluted from the agar plug in 1 ml of SM buffer containing 20 μl chloroform, as described in Maniatis et al. (1982). The phages obtained were purified by repeating the procedure described above using filter replicas from plates containing 50-100 plaques of the isolated phages. After purification the phages were propagated by plating 5×103phages on NZYCM medium. After overnight incubation at 37° C. confluent plates were obtained, from which the phages were eluted by adding 5 ml SM buffer and storing the plate for 2 h. at 4° C. with intermittent shaking. After collection of the supernatant using a pipette, the bacteria were removed from the solution by centrifugation at 4,000×g for 10 min. at 4° C. To the supernatant 0.3% chloroform was added and the number of pfu was determined. These phage stocks contain approximately 109pfu/ml. DNA of four selected phages G15-G18, isolated as described in Sambrook et al 1989. was analyzed by Southern analysis. The DNA was digested for 5 h. at 37° C. in a reaction mixture composed of the following solutions; 5 μl (≈1 μg) DNA solution; 2 μl of the appropriate 10×React buffer (Life Technologies); 10 U Restriction enzyme (Life Technologies) and sterile distilled water to give a final volume of 20 μl. The samples were incubated for 10 min. at 65° C. and rapidly cooled on ice, before loading on a 0.6% agarose gel in 1*TAE buffer. The DNA fragments were separated by electrophoresis at 25 V for 15-18 h. After electrophoresis the DNA was transferred and denatured by alkaline vacuum blotting (VacuGene XL, Pharmacia LKB) to nylon membrane (Hybond N, Amserham) as described in the VacuGene XL instruction manual (pp. 25-26) and subsequently prehybridised and hybridized using the labelled 2.5 kb EcoRI/XhoI fragment of cDNA clone#4 and hybridisation conditions as described. The hybridisation pattern was obtained by exposure of Kodak XAR-5 X-ray film for 18 h. at −70° C. using an intensifying screen. In all four clones fragments originating from the same genomic region were found for which a restriction map was constructed (FIG. 4). Based on the restriction map a 3.6 kb PstI fragment was selected for subcloning. 100 ng pEMBL19 PstI digested fragment was mixed with 250 ng 3.8 kb PstI fragment and 4 μl 5*ligation buffer (composition; 500 mM Tris-HCl, pH 7.6; 100 mM MgCl2; 10 mM ATP; 10 mM dithiothreitol; 25% PEG-6000) and 1 μl (1.2 U/μl) T4DNA ligase (Life Technologies) was added to this mixture in a final volume of 20 μl. After incubation for 16 h at 14° C. the mixture was diluted to 100 μl with sterile water. 10 μl of the diluted mixture was used to transform 250 ml of culture medium, which consists of MM supplemented with 2% glucose, 0.5% yeast extract, 0.2% casamino acids (Vitamin free), 2 mM leucine, 10 μM nicotinamide, 10 mM uridine, was inoculated with 1*106spores per ml of strain NW155 (cspA1, argB13, pyrA6, nicA1, leuA1, prtF28) (derived from NW228, Van den Hombergh et al, 1995) and mycelium was grown for 16-18 hours at 30° C. and 250 rpm in a orbital New Brunswick shaker. The mycelium was harvested on Myracloth (nylon gauze) using a Büchner funnel and mild suction and was washed several times with SP6 (SP6: 0.8% NaCl, 10 mM Na-phosphate buffer pH 6.0). 150 mg Novozyme 234 was dissolved in 20 ml SMC (SMC: 1.33 M sorbitol, 50 mM CaCl2, 20 mM MES buffer, pH 5.8) to which 1 g (wet weight) mycelium was added and which was carefully re-suspended. This suspension was incubated with gentle shaking for 1-2 hours at 30° C., every 30 minutes the mycelium was carefully resuspended and a sample was taken to monitor protoplast formation using a haemocytometer to count the protoplasts. When sufficient protoplasts were present (more then 1*108) these were carefully resuspended and the mycelial debris was removed by filtration over a sterile glasswool plug. The protoplasts were collected by 10 minutes centrifugation at 3000 rpm and 4° C. in a bench centrifuge, the supernatant was removed and the pellet was carefully resuspended in 5 ml STC (STC: 1.33 M Sorbitol, 50 mM CaCl2, 10 mM Tris/HCl, pH 7.5). This wash step was repeated twice and the protoplasts were finally resuspended in STC at a density of 1*108per ml. The transformation was performed by adding 20 μg of pIM200 DNA and 5 μg pGW635, containing the The transformants from pIM200 obtained in Example 7 were analyzed phenotypically by plating on MM containing 1% oat spelt xylan and 1 mM 4-methylumbelliferyl-β-D-xyloside. Of the 26 transformants tested, five had an increased fluorescence. These transformants, together with a PYR+ transformant as a reference, were grown on MM containing 1% oat spelt xylan for 20, 27 and 42 hrs, after which the β-xylosidase activity towards PNP-X was measured. The results are summarised in Table C. An increased level of β-xylosidase activity was found in all five transformants selected, the highest level being more then 30 times the wild-type activity. These results were confirmed by Western blot analysis, using the anti β-xylosidase antibody, prepared as described in Example 3, and the Bio-Rad Immun-blot GAR-AP assay kit following the suppliers instructions. The sequence of the For nucleotide sequence analysis, restriction fragments were isolated which were then cloned in pEMBL18/19 DNA vectors and digested with the appropriate restriction enzymes. The nucleotide sequences were determined by the dideoxynucleotide chain-termination procedure (Sanger et al., 1977) using the Pharmacia T7 DNA polymerase sequencing kit. Computer analysis was done using the PC/GENE program (Intelligenetics). The sequence determined is given in SEQ ID NO:1. The sequence comprising the xlnD structural gene (SEQ ID NO:1) is preceded by a 854 nucleotide long upstream region. A putative TATA box is found at position 787-794. The structural part of the xlnD gene ranges from position 855 till position 3266 and contains no introns, as was certified by sequencing both the cDNA fragment as well as the genomic fragment in pIM200. The xlnD gene encodes a protein of 804 amino acids. The N-terminal amino acid sequence is preceded by a 26 amino acids long hydrophobic sequence, which presumably corresponds to the signal sequence. The mature β-xylosidase protein is 778 amino acids in length, and has a deduced molecular weight of 84,727 Da. For the screening of the This screening resulted in about 10 positive phages which were all purified. Each positive plaque was picked from the plate using a Pasteur pipette and the phages were eluted from the agar plug in 1 ml of SM buffer containing 20 μl chloroform, as described in Maniatis et al. (1982). The phages obtained were purified by repeating the procedure described above using filter replicas from plates containing 50-100 plaques of the isolated phages. After purification the phages were propagated by plating 5×103phages on NZYCM medium. After overnight incubation at 37° C. confluent plates were obtained, from which the phages were eluted by adding 5 ml SM buffer and storing the plate for 2 h. at 4° C. with intermittent shaking. After collection of the supematant using a pipette, the bacteria were removed from the solution by centrifugation at 4,000 ×g for 10 min. at 4° C. To the supernatant 0.3% chloroform was added and the number of pfu is determined. These phage stocks contain approximately 109pfu/ml. The gene disruption plasmids pIM203 and pIM204 were constructed by generating an internal fragment of the xlnD gene by PCR. The fragment was generated using the oligonucleotides derived from the xlnD sequence (SEQ ID NO: 1). Xylos001 was derived from positions 1157 till 1176 and xylos004 was derived from positions 3147 till 3164. The fragment was generated by PCR containing 10 μl 10*reaction buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 15 mM MgCl2, 0.01% gelatine), 16 μl 1.25 mM of each of the four deoxynucleotide triphosphates, 1 ng of the plasmid pIM200 DNA and 1 μg of each of the oligonucleotides in a final volume of 100 μl. This reaction mixture was mixed and 1 μl TAQ polymerase (5 U/μl) (Life Technologies) was added. The DNA was denatured by incubation for 3 min at 92° C. followed by 25 cycli of 1 min 92° C., 1,5 min 52° C. and 1,5 min 72° C. After these 25 cycli the mixture was incubated for 5 min at 72° C. Analysis of the reaction products by agarose electrophoresis revealed a fragment of about 2000 bp, which corresponds to the size expected, based on the sequence of the gene. The resulting fragment was subcloned in the vector pGEM-T (Promega) resulting in the plasmid pIM202. Plasmid pIM203 was constructed by ligation of a SmaI/PstI fragment of pILJ16 (Johnstone et al., 1985), containing the The plasmids containing the xlnD internal fragment as well as the argB gene (pIM203) or the pyrA gene (pIM204), as described in Example 11.1, as a selection marker in transformation, were used to disrupt the To determine the effect of xlnD expression on the expression of the xylanolytic spectrum, The culture filtrates were subsequently analyzed by HPLC analysis, using a Dionex system and Pulsed Amperometric Detection. For this 1 ml of culture filtrate was boiled immediately after harvesting, to inactivate the xylanolytic enzymes, after which the sample was centrifuged for 10 min. (14.000 rpm at 4° C., Eppendorf centrifuge). The resulting supematant was diluted 5-fold in bidest and 20 μl was analyzed by HPLC using a Dionex CarboPac 100 column. The analysis indicated that, while in the wild-type and in the over-expression transformants only in the initial stage xylose oligomers could be detected in the culture filtrate, in the disruption mutant xylobiose and to a lesser extend xylotriose accumulated in the culture filtrate, thus resulting in a source for xylooligomers, in particular xylobiose and xylotriose. The plasmid pIM200 was introduced into From this screening, five transformants were selected to determine β-xylosidase activity. The To analyse whether it is possible to isolate the xlnD counterpart from other fungi by heterologous hybridisation, using the 2.5 kb PstI/NsiI fragment of the xlnD gene as a probe, DNA was isolated from the following strains; As a result hybridising fragments were found for all fungi analysed, very strong hybridisation signals were found in The strain N902::200-18, harbouring multiple copies (about 6) of the Aviv, H. and Leder, P. (1972) Balance D. J. and Turner G. C. (1985) Dekker, R. F. H. (1983) Flipphi, M. J. A., Visser, J., van der Veen, P. and De Graaff, L. H. (1994) Garcia-Campayo and Wood (1993) De Graaff L. H., Van den Broeck, H. C., Van Ooijen A. J. J. and Visser, J. (1994) Harrsen, J. A. M., Kusters-van Someren, M. A., Visser, J. (1990) Hombergh van den, J. P. T. W., van de Vondervoort, P. J. I., van der Heijden, N. C. B. A., and Visser, J. (1995) Johnstone, I. L., Hughes, S. G., Clutterbuck A. J. (1985) Kinoshita K., Takano, M., Koseki, T., Ito. and Iwano, K. (1995). J. of Ferment. and Bioeng.:79, no 5, 422-428. Kormelink, F., Searle-Van Leeuwen, M. J. F., Wood, T. M. and Voragen, A. G. J. (1993) Maniatis, T., Fritsch, E. F. and Sambrook, J. (1982) Poutanen and Puls Rodionova, N. A., Tavobilov, I. M. and Bezborodov, A. M. Sambrook, J., Fritsch, E. F. and Maniatis T. (1989) Sanger, F., Nickelsen, S. and Coulson A. R. (1977) Schutte, J. B. (1991), Nutritional value and physiological effects of D-xylose and L-arabinose in poultry and pigs. Upshall, A., Gilbert, T., Saari G., O'Hara, P. J., Weglenski, P., Berse, B., Miller, K. and Timberlake, W. E. (1986) Utt, E. A., Eddy, C. K., HEshav, K. F. and Ingram, L. O. (1991) Vishniac, W. and Santer, M. (1957) Whittington, H., Kerry-Williams, S., Bidgood, K., Dodsworth, N., Peberdy., J., Dobson, M., Hinchcliffe, E., and Ballance, D. J. (1990). Young, R. A. and Davies, R. W. (1983) BACKGROUND
DESCRIPTION OF THE INVENTION
Activity and inhibition of β-xylosidases of the invention (X-I and X-II), compared to the β-xylosidase according to Rodionova et al. (1983) substrate X-I X-II β-xyl activity (U/mg) invention invention (Rodionova) p-nitrophenyl-β-D-xylopyranoside 60.2 60.9 35.2 p-nitrophenyl-β-D-glucopyranoside 0.2 0.3 7.9 p-nitrophenyl-β-D- 0.0 0.0 0.6 galactopyranoside p-nitrophenyl-α-L- 2.8 3.4 5.8 arabinofuranoside inhibition Ki(mM xylosc) 9.8 13.2 2.9 Amino acid composition of β-xylosidase according to SEQ ID NO. 1, compared to the β-xylosidase according to Rodionova et al. mole % Amino acid number mole % (Rodionova) Ala 86 11.1 8.2 Arg 27 3.5 2.1 Asn + Asp 95 12.2 5.6 Cys 7 0.9 1.1 Gln + Glu 74 9.5 12.4 Gly 63 8.0 11.3 His 13 1.7 1.4 Ile 39 5.0 4.8 Leu 69 8.9 8.8 Lys 24 3.1 2.9 Met 6 0.8 3.3 Phe 24 3.1 2.9 Pro 39 5.0 8.6 Ser 53 6.8 8.7 Thr 58 7.5 7.0 Trp 15 2.0 2.6 Tyr 41 5.3 3.4 Val 45 5.8 6.1 EXAMPLE 1
Purification of
EXAMPLE 2
Construction of a cDNA Expression Library
EXAMPLE 3
Preparation of Antibodies Against β-xylosidase
EXAMPLE 4
Immunoscreening of the
EXAMPLE 5
Analysis of β-xylosidase Expressing cDNA Clones
EXAMPLE 6
Screening of the
EXAMPLE 7
Transformation of
EXAMPLE 8
Analysis of Transformants
β-xylosidase activities in activity (mU/ml culture filtrate) after: 20 hr 27 hr 42 hr pGW 635 15 16 17 XlsA1 82 86 51 XlsA4 90 112 78 XlsA8 211 239 384 XlsA9 63 110 74 XlsA12 96 295 527 EXAMPLE 9
The Primary Structure of the xlnD Gene
9.1: Sequence Analysis of the
9.2: Description of the xlnD Gene
EXAMPLE 10
Screening of the
EXAMPLE 11
Disruption of the
11.1: Construction of the Disruption Plasmids pIM203 and pIM204
11.2: Disruption of the xlnD Gene in
11.3: Effect of Overexpression and Inactivation of xlnD Gene on the Expression of Xylanolytic System of
EXAMPLE 12
Expression of the
WG096 (Wt) 16 0 G191::200-5 725 48 G191::200-7 96 11 G191::200-9 249 40 G191::200-13 520 33 G191::200-15 1525 210 EXAMPLE 13
Screening Filamentous Fungi for the xlnD Gene
EXAMPLE 14
Effect of xlnR Gene Dosage on the Expression of the
REFERENCES